Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace environment.

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

The heritage of Boehringer Ingelheim in developing medicines for ... Specifically for COPD, our products have been on the market for more than 40 years. Looking ahead, our aim is to significantly ...

In the future, around one third of the new products at Boehringer Ingelheim will come from oncology." New high-tech facility Newest technologies and laboratories allow scientists to faster achieve ...

3 In addition, Boehringer ... Medical Products Administration (NMPA), which granted it Breakthrough Therapy designation in June 2024. Survodutide is licensed to Boehringer Ingelheim from Zealand ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well ... throughout our clinical development until the product is on the market. We bring in the patients ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...